iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential

Ibio ( (IBIO) ) just unveiled an update.

On March 9, 2026, iBio reported preclinical body composition data from an obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody for fat-selective weight loss and related cardiometabolic conditions. In this small, not statistically powered study, two once-every-eight-week doses of IBIO-610 cut visceral fat by 6.7% and total fat mass by 5.2% versus vehicle, with only a slight increase in lean mass, mirroring earlier rodent findings and results seen by others targeting the Activin E pathway in humans.

The company said previously disclosed data from the same study showed IBIO-610 has an extended half-life of 33.2 days in obese primates, supporting projections of up to twice-yearly dosing in humans and underlining its bid to position the drug as a differentiated obesity and cardiometabolic therapy. Alongside the obesity program, iBio also updated its corporate presentation to highlight a strategic push into the cardiopulmonary arena, including pulmonary hypertension in heart failure with preserved ejection fraction, using its myostatin x Activin A bispecific antibody platform as a potential next-generation treatment approach.

The most recent analyst rating on (IBIO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

Spark’s Take on IBIO Stock

According to Spark, TipRanks’ AI Analyst, IBIO is a Neutral.

The score is held back primarily by weak financial performance (minimal and declining revenue, large losses, and substantial cash burn), partially offset by improved balance-sheet leverage. Technicals are supportive with a strong uptrend versus moving averages, but stretched momentum indicators add risk. Corporate actions are mixed: runway-extending financing is positive, while ending the ATM program reduces one source of funding flexibility.

To see Spark’s full report on IBIO stock, click here.

More about Ibio

iBio, Inc., based in San Diego and listed on Nasdaq as IBIO, is an AI-driven biotechnology company developing next-generation antibody therapies for obesity, cardiometabolic and cardiopulmonary diseases, as well as other hard-to-treat conditions. The company leverages proprietary 3D modeling and advanced computational biology platforms to build a pipeline of precision biopharmaceuticals targeting significant unmet medical needs.

iBio applies its AI-enabled discovery engine to complex biological pathways implicated in metabolic and cardiopulmonary disorders, aiming to accelerate drug discovery and development timelines. Its research focus includes novel antibody candidates such as Activin-pathway modulators and bispecific antibodies designed to offer differentiated efficacy profiles and convenient dosing for patients.

Average Trading Volume: 3,270,677

Technical Sentiment Signal: Hold

Current Market Cap: $90.16M

See more data about IBIO stock on TipRanks’ Stock Analysis page.